2024
Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis
Chintoh A, Liu L, Braun A, Akseer S, Bearden C, Cadenhead K, Cornblatt B, Keshavan M, Mathalon D, McGlashan T, Perkins D, Seidman L, Stone W, Tsuang M, Walker E, Woods S, Cannon T, Addington J. Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis. Schizophrenia Research 2024, 271: 153-160. PMID: 39029145, DOI: 10.1016/j.schres.2024.07.030.Peer-Reviewed Original ResearchClinical high riskClinical high-risk individualsSex differencesNegative symptomsTransition to psychosisInvestigate sex differencesNo sex differencesSchizophreniform disorderCHR individualsPsychosisSubstance useSchizophreniaSymptomsHigh riskIndividualsSchizophreniformAnxietyClinical presentationSexDepressionDisordersBaselineDifferencesMaleYouthThe Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program
Ferrara M, Basaldella M, Vacca F, Woods S, Walsh B, Cannon T, Srihari V, Grassi L. The Italian adaptation of the Mini‐SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program. Early Intervention In Psychiatry 2024 PMID: 38769052, DOI: 10.1111/eip.13548.Peer-Reviewed Original ResearchClinical high riskFirst-episode psychosisDSM-5-Attenuated Psychosis SyndromeItalian adaptationPsychosis syndromeDSM-5FEP programsEarly stages of psychosisItalian versionFirst-episode psychosis servicesFull-blown psychosisStages of psychosisEpisode of psychosisClinical structured interviewEpisode psychosisEstablished psychosisTrained psychologistsPsychiatric historyPsychosisPsychosis servicesHigh riskStructured interviewsClinical settingEarly detection of individualsAssess validity12. Reduced P300 Responses Are Associated With Altered Excitatory and Inhibitory Cell Function in High-Risk Individuals who Convert to Psychosis: Insights From the NAPLS-2 Sample
Rodriguez-Sanchez J, Hauke D, Friston K, Cannon T, Mathalon D, Adams R. 12. Reduced P300 Responses Are Associated With Altered Excitatory and Inhibitory Cell Function in High-Risk Individuals who Convert to Psychosis: Insights From the NAPLS-2 Sample. Biological Psychiatry 2024, 95: s79. DOI: 10.1016/j.biopsych.2024.02.190.Peer-Reviewed Original ResearchSocial Engagement Moderates Relations Between Hippocampal-Temporoparietal Junction Connectivity and Neighborhood Social Fragmentation in Youth at Clinical High Risk for Psychosis
Aberizk K, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Tsuang M, Woods S, Walker E, Ku B. Social Engagement Moderates Relations Between Hippocampal-Temporoparietal Junction Connectivity and Neighborhood Social Fragmentation in Youth at Clinical High Risk for Psychosis. Biological Psychiatry 2024, 95: s37-s38. DOI: 10.1016/j.biopsych.2024.02.095.Peer-Reviewed Original Research451. Group Iterative Multiple Model Estimation Reveals Individuals at Clinical High-Risk for Psychosis and Healthy Comparisons Self-Organize by Premorbid Adjustment According to Patterns of Temporoparietal Brain Connectivity
Aberizk K, Ku B, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Stone W, Tsuang M, Woods S, Walker E. 451. Group Iterative Multiple Model Estimation Reveals Individuals at Clinical High-Risk for Psychosis and Healthy Comparisons Self-Organize by Premorbid Adjustment According to Patterns of Temporoparietal Brain Connectivity. Biological Psychiatry 2024, 95: s284. DOI: 10.1016/j.biopsych.2024.02.950.Peer-Reviewed Original ResearchRace/ethnicity and socioeconomic status as predictors of outcome following family therapy in youth at clinical high risk for psychosis
Ruiz‐Yu B, Le T, Weintraub M, Zinberg J, Addington J, O'Brien M, Walsh B, Friedman‐Yakoobian M, Auther A, Cornblatt, Domingues I, Cannon T, Miklowitz D, Bearden C. Race/ethnicity and socioeconomic status as predictors of outcome following family therapy in youth at clinical high risk for psychosis. Early Intervention In Psychiatry 2024 PMID: 38676463, DOI: 10.1111/eip.13541.Peer-Reviewed Original ResearchClinical high riskNegative symptomsFamily therapyRandomized trial of family-focused therapyGlobal functioningEffect of race/ethnicityNHW participantsTrial of family therapyFamily-focused therapyParental educationAssociated with greater improvementSociodemographic factorsSocioeconomic statusPositive symptomsPsychosocial treatmentsPsychosocial functioningHigher parental educationFollow-up measurementsHigh riskInfluence of race/ethnicityGreater improvementRandomized trialsTreatment outcomesPsychosisPredictors of outcomeAccelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needsProteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study
Byrne J, Healy C, Föcking M, Susai S, Mongan D, Wynne K, Kodosaki E, Heurich M, de Haan L, Hickie I, Smesny S, Thompson A, Markulev C, Young A, Schäfer M, Riecher-Rössler A, Mossaheb N, Berger G, Schlögelhofer M, Nordentoft M, Chen E, Verma S, Nieman D, Woods S, Cornblatt B, Stone W, Mathalon D, Bearden C, Cadenhead K, Addington J, Walker E, Cannon T, Cannon M, McGorry P, Amminger P, Cagney G, Nelson B, Jeffries C, Perkins D, Cotter D. Proteomic Biomarkers for the Prediction of Transition to Psychosis in Individuals at Clinical High Risk: A Multi-cohort Model Development Study. Schizophrenia Bulletin 2024, 50: 579-588. PMID: 38243809, PMCID: PMC11059811, DOI: 10.1093/schbul/sbad184.Peer-Reviewed Original ResearchClinical high riskTransition to psychosisAssociated with transition to psychosisClinical high-risk cohortNorth American Prodrome Longitudinal Study 2Predicting transition to psychosisDevelopment of psychosisLongitudinal Study 2Group levelPlasma proteomics dataCHR participantsPsychosis riskPrediction of transitionPsychosisStudy 2High riskLongitudinal associationsStudy follow-up periodRandomized controlled trialsLogistic regression modelsMultiple comparisonsPrimary outcomeProteomic biomarkersControlled trialsGlycoprotein 1Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms
Healy C, Byrne J, Raj Suasi S, Föcking M, Mongan D, Kodosaki E, Heurich M, Cagney G, Wynne K, Bearden C, Woods S, Cornblatt B, Mathalon D, Stone W, Cannon T, Addington J, Cadenhead K, Perkins D, Jeffries C, Cotter D. Differential expression of haptoglobin in individuals at clinical high risk of psychosis and its association with global functioning and clinical symptoms. Brain Behavior And Immunity 2024, 117: 175-180. PMID: 38219978, DOI: 10.1016/j.bbi.2023.12.018.Peer-Reviewed Original ResearchGlobal Assessment of Functioning ScaleNorth American Prodrome Longitudinal StudyClinical high riskPoor functionScale of Psychosis-risk SymptomsPsychosis-risk symptomsAssociated with poorer functioningFirst-episode psychosisTransition to psychosisGreater symptom severityFollow-upIndividuals at-riskClinical symptomsPsychotic disordersHigh riskSymptom severityPsychosocial functioningGlobal functioningPsychosisSubscale scoresFDR correctionAcute phase inflammatory responseLongitudinal studyGlobal assessmentFunctional scales
2023
Linking enlarged choroid plexus with plasma analyte and structural phenotypes in clinical high risk for psychosis: A multisite neuroimaging study
Bannai D, Reuter M, Hegde R, Hoang D, Adhan I, Gandu S, Pong S, Raymond N, Zeng V, Chung Y, He G, Sun D, van Erp T, Addington J, Bearden C, Cadenhead K, Cornblatt B, Mathalon D, McGlashan T, Jeffries C, Stone W, Tsuang M, Walker E, Woods S, Cannon T, Perkins D, Keshavan M, Lizano P. Linking enlarged choroid plexus with plasma analyte and structural phenotypes in clinical high risk for psychosis: A multisite neuroimaging study. Brain Behavior And Immunity 2023, 117: 70-79. PMID: 38169244, PMCID: PMC10932816, DOI: 10.1016/j.bbi.2023.12.021.Peer-Reviewed Original ResearchNorth American Prodrome Longitudinal Study 2Plasma analytesTotal white matter volumeChoroid plexus enlargementLarger lateral ventricle volumesLateral ventricle volumeWhite matter volumeClinical high riskSubcortical gray matterChronic psychosisNeuroanatomical alterationsBaseline scanPsychosis onsetHigh riskChoroid plexusMatter volumeVentricle volumeConversion statusGray matterNeuroimaging studiesPsychosisStructural phenotypesImportant biomarkerEnlargementLongitudinal Study 2